Solventum Corp
No SEC Form 4 filings for $SOLV in the last 30 days.
Solventum said it will separate its health information systems software business, leaving MedSurg and Dental Solutions, as part of its turnaround. The unit accounted for 16.3% of 2025 sales. Solventum raised 2026 organic sales growth to 2.5% to 3% and adjusted profit per share to $7.10 to $7.20. Q2 adjusted EPS was $2.55 on revenue of $2.21B, beating LSEG estimates.
Solventum (NYSE:SOLV) reported Q2 CY2026 results with revenue up 2.2% year on year to $2.21 billion, beating market expectations. Non-GAAP EPS was $2.55, 33.8% above analysts’ consensus. The article also cites trailing 12-month sales of $8.31 billion, flat over two years, and Q2 free cash flow of $144 million. Shares rose 3.7% to $90.75.
Solventum (NYSE: SOLV) reported Q2 2026 sales of $2.2 billion, up 2.2% reported and 9.5% organic. GAAP diluted EPS was $0.53, adjusted $2.55. Operating cash flow was $227 million and free cash flow $144 million. The company said it intends to separate its Health Information Systems segment and raised full-year 2026 guidance for organic sales growth, adjusted EPS and free cash flow.
Over the past 7 days, alphai's AI scored 4 news stories mentioning SOLV (Solventum Corp). Coverage has skewed bullish: 4 bullish, 0 neutral, and 0 bearish.
Recent SOLV coverage spans earnings, financial news and corporate actions.
Guidance upside plus a non-core divestiture plan should re-rate the turnaround narrative, with near-term focus on execution and margin/organic growth sustainability.
Earnings beat with modest top-line growth and strong EPS outperformance suggests near-term sentiment support, but flat forward revenue expectations limit upside conviction.
Raised 2026 guidance plus a planned separation of the Health Information Systems segment are likely to re-rate expectations for growth and margin trajectory.
Guidance increases and stronger organic sales growth are likely to support near-term sentiment, while GAAP margin and net income weakness reflect separation and legal costs.
Earnings preview centers on consensus EPS and the market’s concerns about weak growth and deteriorating free-cash-flow margins.
alphai scores every news story that mentions SOLV with an AI model for sentiment and relevance, and aggregates insider trades from Solventum Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Solventum said it will separate its health information systems software business, leaving MedSurg and Dental Solutions, as part of its turnaround. The unit accounted for 16.3% of 2025 sales. Solventum raised 2026 organic sales growth to 2.5% to 3% and adjusted profit per share to $7.10 to $7.20. Q2 adjusted EPS was $2.55 on revenue of $2.21B, beating LSEG estimates.
4 min readSolventum (NYSE:SOLV) reported Q2 CY2026 results with revenue up 2.2% year on year to $2.21 billion, beating market expectations. Non-GAAP EPS was $2.55, 33.8% above analysts’ consensus. The article also cites trailing 12-month sales of $8.31 billion, flat over two years, and Q2 free cash flow of $144 million. Shares rose 3.7% to $90.75.
5 min readSolventum (NYSE: SOLV) reported Q2 2026 sales of $2.2 billion, up 2.2% reported and 9.5% organic. GAAP diluted EPS was $0.53, adjusted $2.55. Operating cash flow was $227 million and free cash flow $144 million. The company said it intends to separate its Health Information Systems segment and raised full-year 2026 guidance for organic sales growth, adjusted EPS and free cash flow.
4 min readSolventum Corp (SOLV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026-8kerexx991.htm EX-99.1 Document Exhibit 99.1 Solventum Reports Second Quarter 2026 Financial Results • R eported sales increased 2.2%; organic sales increased 9.5% • Announces intent to separate its Health Information Systems business segment • Increases full-yea
6 min readSolventum (SOLV) is set to report Q2 2026 earnings on Aug. 5 after market close. Analysts expect diluted EPS of $1.91, up from $1.69 a year earlier, and full-year EPS of $6.58. The article cites a Moderate Buy consensus and an average $83.67 price target, while noting concerns over weak growth and deteriorating free cash flow margins.
3 min readRenewAtlas and Wiki-Solar report that Indian solar EPC and O&M capacity under development rose 18% year over year, with Larsen & Toubro and Sterling & Wilson among top operators. L&T has 13.2GW across operating and under-development EPC capacity and 70 projects. SECI tendered 1.2GW solar PV plus 600MW/3.6GWh BESS, supporting demand for large ISTS-connected hybrids.
6 min readSolventum Corp (SOLV) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. solv-20260716 FALSE 0001964738 0001964738 2026-07-16 2026-07-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported):
2 min readSol Systems said it reached financial close on a 123MW Illinois solar portfolio worth US$355 million. The projects are expected to produce about 280,000MWh in the first year and secured revenue support via Illinois Power Agency Indexed REC Procurement. SOLV Energy (appointed EPC) and a financing group including BBVA, ING, Intesa, NAB, Natixis and NatWest are involved, with tax equity from Raymond James.
3 min readMizuho, via Investing.com, highlighted seven U.S. healthcare stocks for growth, citing clinical catalysts and operational updates. Price targets and ratings include EYPT $36, PCVX $163, ERAS $26, ARQT $35, LNTH $115, EHC $134, and SOLV $100. Key items include EYPT Phase 3 data in Aug 2026, PCVX Phase 3 in 4Q 2026, and LNTH PDUFA mid-Aug 2026.
4 min readSolventum (NYSE: SOLV) saw multiple analyst rating and target changes. Wedbush initiated coverage with an “outperform” rating and $94 target (5/15/26). UBS downgraded to “neutral” with $50 target (5/14/26) and previously cut its target to $78 (5/6/26). Other firms adjusted targets and ratings on 5/6/26, including Stifel ($90, buy), KeyCorp ($93, overweight), Wells Fargo ($70, equal weight), and BTIG ($89, buy). Director Amy Mcbride Wendell bought 1,475 shares at $68.03 (3/10/26).
1 min read
